Navigation Links
Shanghai ChemPartner Announces Being Selected as Antibody Service Partner by Shenogen Pharma Group
Date:3/16/2011

SHANGHAI, March 16, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.  Shenogen Pharma Group is a China-based drug development venture that develops innovative therapeutics for the treatment of oncology indications including breast cancer and leukemia.

"We have evaluated multiple potential antibody development service partners in China," said Dr. Xueming Qian, who joined Shenogen as Vice President of Biology and Antibody Technology last June after working for twelve years in Amgen's discovery research group at its Thousand Oaks, California site.  "We decided to work with ChemPartner's Biologics Services team because they have the required therapeutic antibody drug research and development experience, expertise and people to support our therapeutic antibody program."

ChemPartner will be responsible for a spectrum of drug discovery activities for an integrated antibody drug development program including target protein production and cell line development, lead antibody generation and optimization (humanization and affinity maturation), assay development, protein analytics, DMPK, and in vivo pharmacology.

Dr. Chengbin Wu, Vice President of Biologics Services of ChemPartner, added, "We are delighted that Shenogen, an innovative drug development company, chose ChemPartner as its preferred outsource partner for antibody drug development.  Shenogen has a world-class management team and exclusive global intellectual property rights on a novel target (ER-alpha 36), and we fully anticipate that ChemPartner's outsource service will facilitate the rapid advancement of Shenogen's antibody pipeline projects into development stage and beyond."

About Shenogen Pharma GroupShenogen Pharma Group is a privately held drug development venture that develops novel therapeutics targeting a membrane-bound estrogen receptor, ER-alpha 36, for the treatment of oncology indications. Shenogen collaborates extensively with key U.S. and China-based research and development partners to advance its pipeline projects. Shenogen has a pipeline of small molecule and antibody therapeutics, and its first lead compound is being evaluated in phase I clinical trial for oncology indications. For more information, please visit www.shenogen.com.cn.

About ShangPharma CorporationShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.ShangPharma CorporationLan Xie, VP of Finance and OperationsIR@shangpharma.comorChristensenIn New YorkKimberly Minarovich, +1-917-533-3268kminarovich@christensenir.comorIn Hong KongTip Fleming, +852-9212-0684tfleming@christensenir.com
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
2. American Scientific Resources Inc. Opens Shanghai Location
3. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
4. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
5. China-Biotics to Host Investor Day in Shanghai to Discuss Corporate Development Strategy
6. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
7. Special Event Providing Exclusive Access to Shanghais Booming Zhangjiang Pharma Valley Added to Agenda of First Annual SBS China Conference
8. Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai
9. NSF International Opens NSF Shanghai Testing Laboratory in China to Support Increasing Demand for Testing and Certification Services
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... A stressful ... at work can also decrease overall productivity and performance in the workplace. The goal ... , During the last few weeks of April, Clearview Resolution Services will be shutting ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
Breaking Medicine News(10 mins):